IperionX Exhibits Operational Progress Amid Price Weakness

Despite continuous weakness in its share price, IperionX continues to advance its strategic initiatives and operational milestones. Take a look at the latest developments shaping the company’s long-term growth story.

IperionX Limited (ASX: IPX)

IperionX Limited (ASX: IPX), on 30 July 2026, has released its quarterly report for the period ended 30 June 2026, which marks the close of FY26 for the company. It is followed by the March quarterly report when the company guided a cash balance of between US$36 million and US$40 million by the end of the year as its Virginia Titanium Manufacturing Campus moved from commissioning into consistent and continuous production. IperionX has a market capitalisation of $1.11 billion and has continued to improve its proprietary HAMR and HSPT technologies through the June quarter toward a targeted run-rate of roughly 200 tonnes per annum of titanium powder by the end of CY26 while also enhancing downstream press and sintering capacity to support customer qualification across defence, aerospace and consumer-electronics programs. Notably, the balance sheet flagged in this report was reinforced just weeks later by fresh US capital markets funding.

IperionX was awarded up to US$6.6 million on 1 July 2026, under a U.S. Department of War program run through the Office of the Secretary of War's Submarine Workforce and Industrial Base initiative which aimed at expansion of domestic production of ballistic grade titanium plate for maritime and land defence platforms. Alongside that award, the U.S. Army's Ground Vehicle Systems Center placed a purchase order for titanium fasteners destined for the Joint Light Tactical Vehicle, which supports IperionX's growing footprint in the American defence-industrial supply chain.

Later on 2 July 2026, the company completed its strategic Camden acquisition which helped it take ownership of critical mineral and infrastructure assets in Tennessee immediately adjacent to the flagship Titan Project. The Camden package adds roughly 70 acres of ultra-high-grade surface stockpiles grading up to 23% heavy mineral concentrate. It also adds around 180 acres of pre-stripped mineralisation and existing grid power, water, gas and rail access, infrastructure that could support a low capital and stockpile-first development path for the combined Titan-Camden platform.

IperionX also strengthened its funding position through early July, pricing an underwritten public offering of 2,275,000 American Depositary Shares at US$21.98 each for gross proceeds of close to US$50 million. The resulting new securities were quoted on the ASX around 8 July 2026 while the proceeds were to be utilised for commercialisation of the company's titanium technologies, further Virginia campus expansion and continued Titan-Camden pre-development work.

IperionX released the Definitive Feasibility Study for the 100% owned Titan Critical Minerals Project on 4 June 2026 which confirmed an after-tax NPV8 of US$813 million and a 39% internal rate of return over an initial 14 year mine plan producing titanium, zircon and heavy rare earth concentrate, figures that underpinned the Camden acquisition agreed on 15 June 2026.

For Australian investors, a maturing US defence order book along with valuable minerals study and a well-timed capital raise together paint a company entering the new financial year with more clarity than a year ago, even as execution and funding risk on the Titan buildout remain key watch points.

(Source: Company Announcements)